LPCN
Lipocine Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.18
−2.03%Sep 14, 2026, 12:00 UTC
Lipocine Inc. announced the initiation of the BLOOM Phase 3 study evaluating LPCN 1154 (oral brexanolone) for postpartum depression, with first participant dosing expected in early Q4 2026.
Source:Aug 4, 2026, 00:00 UTC
Lipocine Inc. reported its Q2 2026 financial results, with revenue of $190,099 and a net loss of $2,622,595.
Source:Aug 3, 2026, 00:00 UTC
Lipocine Inc. appointed Michael J. Grissinger as a director, effective August 3, 2026, with an initial stock option grant to purchase 2,000 shares of common stock.
Source:Jun 4, 2026, 00:00 UTC
Lipocine Inc. elected Dr. Mahesh V. Patel, John W. Higuchi, Dr. Jill M. Jene, and Dr. Richard Dana Ono as directors effective June 3, 2026.